|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00108095 |
This study is looking at a range of doses of this NK-1 receptor antagonist drug, for both safety and effectiveness in prevention PONV
Condition | Intervention | Phase |
Postoperative Nausea and Vomiting |
Drug: intravenous ondansetron |
Phase II |
MedlinePlus related topics: | Anesthesia Nausea and Vomiting |
ChemIDplus related topics: | Ondansetron Ondansetron hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW67969, When Administered With Intravenous Ondansetron Hydrochloride for the Prevention of Post-Operative Nausea and Vomiting (PONV) and Post-Discharge Nausea and Vomiting (PDNV) in Female Subjects With Known Risk Factors for PONV Who Are Undergoing Surgical Procedures Associated With an Increased Emetogenic Risk |
Estimated Enrollment: | 665 |
Study Start Date: | October 2004 |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Show 69 Study Locations |
GlaxoSmithKline |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Study ID Numbers: | NKT102260 |
First Received: | April 13, 2005 |
Last Updated: | October 5, 2006 |
ClinicalTrials.gov Identifier: | NCT00108095 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|